Effect of pioglitazone on insulin signaling in skeletal and cardiac muscles of high fat-fed zucker rats

A. R. Gosmanov, S. Jones, J. V. St. Peter, Donald Thomason

Research output: Contribution to journalArticle

Abstract

Thiazolidinediones (TZDs) improve glycemic control in patients with diabetes partly by improving glucose utilization by peripheral tissues and enhancing glucose uptake and insulin signaling in skeletal muscle. However, the effects of TZDs on fat-induced derangements of insulin signaling are poorly understood. In this study, we investigated the effects of administration of pioglitazone (PIO) on phosphorylation and expression of key insulin signaling molecules in skeletal and cardiac muscles of high fat-fed fa/fa Zucker rats. Methods: Zucker rats were fed a high-fat diet throughout the study. On study day 7, they were randomly assigned to a control group, 14-day PIO group, or a single-dose PIO group. Single-dose PIO received drug on the last study day via gavage (20 mg/kg). The 14-day PIO group received drug orally via admixture with chow. On study day 21, all animals were sacrificed within 6 hours after the last dose of PIO. Blood and tissues (heart, soleus, and plantaris muscle) were harvested and frozen for Western blot analysis of insulin receptor (InsR), ERK1,2, p38 MAPK, and Akt. Results: Chronic exposure in the 14-day PIO group, but not in the acute group improved glycemia and reduced plasma insulin by 3-fold (p <. 05). In heart muscle, both single and 14-day PIO (a) decreased tyrosine phosphorylation of InsR and Akt on Ser473 by 30-60% (p < .05), (b) increased phosphorylation of p38 by 80% and ERK1,2 by 21-40% (p < .05). In myocardium, both regimens of PIO increased Akt expression by 84-211% (p <.05). In soleus muscle, acute and 14-day PIO reduced InsR phosphorylation by 39% (p >.05) and 60% (p <.05), respectively. In addition, any PIO exposure decreased ERK1,2 expression in soleus muscle. In plantaris muscle, compared to control, single-dose PIO yielded 128-160% (p<.05) increase in phosphorylation of ERK1,2, p38, and Akt. More-over, 14-day PIO showed 180-350% (p <.05) increase in phosphorylation. Any exposure to PIO decreased Akt expression by 22-35% (p < .05). Conclusion: In insulin-resistant high fat-fed rats, administration of both single and 14-day PIO reduced InsR activation in cardiac and skeletal muscle. This was accompanied by activation of MAPKs in heart and plantaris, activation of Akt in plantaris, and no changes in MAPKs and Akt phosphorylation in soleus muscles. Therefore, the study suggests the presence of differential effects of PIO on insulin signaling among different types of striated muscles. The results also demonstrate the effects of acute PIO on muscle insulin signaling without drug effects on hyperglycemia and insulinemia.

Original languageEnglish (US)
JournalJournal of Investigative Medicine
Volume54
Issue number1
StatePublished - Jan 1 2006

Fingerprint

pioglitazone
Zucker Rats
Muscle
Rats
Myocardium
Skeletal Muscle
Fats
Insulin
Phosphorylation
Thiazolidinediones
Chemical activation
Insulin Receptor

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Effect of pioglitazone on insulin signaling in skeletal and cardiac muscles of high fat-fed zucker rats. / Gosmanov, A. R.; Jones, S.; St. Peter, J. V.; Thomason, Donald.

In: Journal of Investigative Medicine, Vol. 54, No. 1, 01.01.2006.

Research output: Contribution to journalArticle

@article{90ff3f07326b4fdf9b0c71edd9d059d1,
title = "Effect of pioglitazone on insulin signaling in skeletal and cardiac muscles of high fat-fed zucker rats",
abstract = "Thiazolidinediones (TZDs) improve glycemic control in patients with diabetes partly by improving glucose utilization by peripheral tissues and enhancing glucose uptake and insulin signaling in skeletal muscle. However, the effects of TZDs on fat-induced derangements of insulin signaling are poorly understood. In this study, we investigated the effects of administration of pioglitazone (PIO) on phosphorylation and expression of key insulin signaling molecules in skeletal and cardiac muscles of high fat-fed fa/fa Zucker rats. Methods: Zucker rats were fed a high-fat diet throughout the study. On study day 7, they were randomly assigned to a control group, 14-day PIO group, or a single-dose PIO group. Single-dose PIO received drug on the last study day via gavage (20 mg/kg). The 14-day PIO group received drug orally via admixture with chow. On study day 21, all animals were sacrificed within 6 hours after the last dose of PIO. Blood and tissues (heart, soleus, and plantaris muscle) were harvested and frozen for Western blot analysis of insulin receptor (InsR), ERK1,2, p38 MAPK, and Akt. Results: Chronic exposure in the 14-day PIO group, but not in the acute group improved glycemia and reduced plasma insulin by 3-fold (p <. 05). In heart muscle, both single and 14-day PIO (a) decreased tyrosine phosphorylation of InsR and Akt on Ser473 by 30-60{\%} (p < .05), (b) increased phosphorylation of p38 by 80{\%} and ERK1,2 by 21-40{\%} (p < .05). In myocardium, both regimens of PIO increased Akt expression by 84-211{\%} (p <.05). In soleus muscle, acute and 14-day PIO reduced InsR phosphorylation by 39{\%} (p >.05) and 60{\%} (p <.05), respectively. In addition, any PIO exposure decreased ERK1,2 expression in soleus muscle. In plantaris muscle, compared to control, single-dose PIO yielded 128-160{\%} (p<.05) increase in phosphorylation of ERK1,2, p38, and Akt. More-over, 14-day PIO showed 180-350{\%} (p <.05) increase in phosphorylation. Any exposure to PIO decreased Akt expression by 22-35{\%} (p < .05). Conclusion: In insulin-resistant high fat-fed rats, administration of both single and 14-day PIO reduced InsR activation in cardiac and skeletal muscle. This was accompanied by activation of MAPKs in heart and plantaris, activation of Akt in plantaris, and no changes in MAPKs and Akt phosphorylation in soleus muscles. Therefore, the study suggests the presence of differential effects of PIO on insulin signaling among different types of striated muscles. The results also demonstrate the effects of acute PIO on muscle insulin signaling without drug effects on hyperglycemia and insulinemia.",
author = "Gosmanov, {A. R.} and S. Jones and {St. Peter}, {J. V.} and Donald Thomason",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
volume = "54",
journal = "Journal of Investigative Medicine",
issn = "1081-5589",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effect of pioglitazone on insulin signaling in skeletal and cardiac muscles of high fat-fed zucker rats

AU - Gosmanov, A. R.

AU - Jones, S.

AU - St. Peter, J. V.

AU - Thomason, Donald

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Thiazolidinediones (TZDs) improve glycemic control in patients with diabetes partly by improving glucose utilization by peripheral tissues and enhancing glucose uptake and insulin signaling in skeletal muscle. However, the effects of TZDs on fat-induced derangements of insulin signaling are poorly understood. In this study, we investigated the effects of administration of pioglitazone (PIO) on phosphorylation and expression of key insulin signaling molecules in skeletal and cardiac muscles of high fat-fed fa/fa Zucker rats. Methods: Zucker rats were fed a high-fat diet throughout the study. On study day 7, they were randomly assigned to a control group, 14-day PIO group, or a single-dose PIO group. Single-dose PIO received drug on the last study day via gavage (20 mg/kg). The 14-day PIO group received drug orally via admixture with chow. On study day 21, all animals were sacrificed within 6 hours after the last dose of PIO. Blood and tissues (heart, soleus, and plantaris muscle) were harvested and frozen for Western blot analysis of insulin receptor (InsR), ERK1,2, p38 MAPK, and Akt. Results: Chronic exposure in the 14-day PIO group, but not in the acute group improved glycemia and reduced plasma insulin by 3-fold (p <. 05). In heart muscle, both single and 14-day PIO (a) decreased tyrosine phosphorylation of InsR and Akt on Ser473 by 30-60% (p < .05), (b) increased phosphorylation of p38 by 80% and ERK1,2 by 21-40% (p < .05). In myocardium, both regimens of PIO increased Akt expression by 84-211% (p <.05). In soleus muscle, acute and 14-day PIO reduced InsR phosphorylation by 39% (p >.05) and 60% (p <.05), respectively. In addition, any PIO exposure decreased ERK1,2 expression in soleus muscle. In plantaris muscle, compared to control, single-dose PIO yielded 128-160% (p<.05) increase in phosphorylation of ERK1,2, p38, and Akt. More-over, 14-day PIO showed 180-350% (p <.05) increase in phosphorylation. Any exposure to PIO decreased Akt expression by 22-35% (p < .05). Conclusion: In insulin-resistant high fat-fed rats, administration of both single and 14-day PIO reduced InsR activation in cardiac and skeletal muscle. This was accompanied by activation of MAPKs in heart and plantaris, activation of Akt in plantaris, and no changes in MAPKs and Akt phosphorylation in soleus muscles. Therefore, the study suggests the presence of differential effects of PIO on insulin signaling among different types of striated muscles. The results also demonstrate the effects of acute PIO on muscle insulin signaling without drug effects on hyperglycemia and insulinemia.

AB - Thiazolidinediones (TZDs) improve glycemic control in patients with diabetes partly by improving glucose utilization by peripheral tissues and enhancing glucose uptake and insulin signaling in skeletal muscle. However, the effects of TZDs on fat-induced derangements of insulin signaling are poorly understood. In this study, we investigated the effects of administration of pioglitazone (PIO) on phosphorylation and expression of key insulin signaling molecules in skeletal and cardiac muscles of high fat-fed fa/fa Zucker rats. Methods: Zucker rats were fed a high-fat diet throughout the study. On study day 7, they were randomly assigned to a control group, 14-day PIO group, or a single-dose PIO group. Single-dose PIO received drug on the last study day via gavage (20 mg/kg). The 14-day PIO group received drug orally via admixture with chow. On study day 21, all animals were sacrificed within 6 hours after the last dose of PIO. Blood and tissues (heart, soleus, and plantaris muscle) were harvested and frozen for Western blot analysis of insulin receptor (InsR), ERK1,2, p38 MAPK, and Akt. Results: Chronic exposure in the 14-day PIO group, but not in the acute group improved glycemia and reduced plasma insulin by 3-fold (p <. 05). In heart muscle, both single and 14-day PIO (a) decreased tyrosine phosphorylation of InsR and Akt on Ser473 by 30-60% (p < .05), (b) increased phosphorylation of p38 by 80% and ERK1,2 by 21-40% (p < .05). In myocardium, both regimens of PIO increased Akt expression by 84-211% (p <.05). In soleus muscle, acute and 14-day PIO reduced InsR phosphorylation by 39% (p >.05) and 60% (p <.05), respectively. In addition, any PIO exposure decreased ERK1,2 expression in soleus muscle. In plantaris muscle, compared to control, single-dose PIO yielded 128-160% (p<.05) increase in phosphorylation of ERK1,2, p38, and Akt. More-over, 14-day PIO showed 180-350% (p <.05) increase in phosphorylation. Any exposure to PIO decreased Akt expression by 22-35% (p < .05). Conclusion: In insulin-resistant high fat-fed rats, administration of both single and 14-day PIO reduced InsR activation in cardiac and skeletal muscle. This was accompanied by activation of MAPKs in heart and plantaris, activation of Akt in plantaris, and no changes in MAPKs and Akt phosphorylation in soleus muscles. Therefore, the study suggests the presence of differential effects of PIO on insulin signaling among different types of striated muscles. The results also demonstrate the effects of acute PIO on muscle insulin signaling without drug effects on hyperglycemia and insulinemia.

UR - http://www.scopus.com/inward/record.url?scp=84921707777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921707777&partnerID=8YFLogxK

M3 - Article

VL - 54

JO - Journal of Investigative Medicine

JF - Journal of Investigative Medicine

SN - 1081-5589

IS - 1

ER -